Control of type 1 diabetes by CD4 +Foxp3+ regulatory T cells: Lessons from mouse models and implications for human disease

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 3, 2009, Pages 208-218

  Sgouroudis, Evridiki ^a   Piccirillo, Ciriaco A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

CD4+CD25+ regulatory T cells; Dendritic cells (DC); Diabetes; Foxp3; IL 2; Tolerance

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; PROINSULIN; THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CELL MATURATION; CELL THERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES CONTROL; DIABETOGENESIS; DISEASE PREDISPOSITION; DRUG MECHANISM; EFFECTOR CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LYMPHOCYTE DEPLETION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; IMMUNOLOGY; MOUSE; PANCREAS; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD4; AUTOIMMUNE DISEASES; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2; MICE; MICE, INBRED NOD; PANCREAS; T-LYMPHOCYTES, REGULATORY;

EID: 65649129352     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.945     Document Type: Review

References (114)

1. Todd JA. Genetic control of autoimmunity in type 1 diabetes. Immunol Today 1990; 11: 122-129.
2. Vaarala O. Is it dietary insulin? Ann N Y Acad Sci 2006; 1079: 350-359.
3. Savilahti E, Saukkonen TT, Virtala ET, Tuomilehto J, Akerblom HK, The Childhood Diabetes in Finland Study Group. Increased levels of cow's milk and beta-lactoglobulin antibodies in young children with newly diagnosed IDDM. Diabetes Care 1993; 16: 984-989.
4. Owerbach D, Lernmark A, Platz P, et al. HLA-D region beta-chain DNA endonuclease fragments differ between HLA-DR identical healthy and insulin-dependent diabetic individuals. Nature 1983; 303: 815-817.
5. Alizadeh BZ, Koeleman BP. Genetic polymorphisms in susceptibility to Type 1 Diabetes. Clin Chim Acta 2008; 387: 9-17.
6. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447-485.
7. Hu Y, Nakagawa Y, Purushotham KR, Humphreys-Beher MG. Functional changes in salivary glands of autoimmune disease-prone NOD mice. Am J Physiol 1992; 263: E607-E614.
8. Many MC, Maniratunga S, Denef JF. The non-obese diabetic (NOD) mouse: an animal model for autoimmune thyroiditis. Exp Clin Endocrinol Diabetes 1996; 104(Suppl. 3): 17-20.
9. Salomon B, Rhee L, Bour-Jordan H, et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med 2001; 194: 677-684.
10. Suri A, Levisetti MG, Unanue ER. Do the peptide-binding properties of diabetogenic class II molecules explain autoreactivity? Curr Opin Immunol 2008; 20: 105-110.
11. Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien YH. Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc Natl Acad Sci U S A 2006; 103: 12475-12480.
12. Homo-Delarche F. Is pancreas development abnormal in the non-obese diabetic mouse, a spontaneous model of type I diabetes? Braz J Med Biol Res 2001; 34: 437-447.
13. Hill NJ, Stotland A, Solomon M, Secrest P, Getzoff E, Sarvetnick N. Resistance of the target islet tissue to autoimmune destruction contributes to genetic susceptibility in Type 1 diabetes. Biol Dir 2007; 2: 5.
14. Grattan M, Mi QS, Meagher C, Delovitch TL. Congenic mapping of the diabetogenic locus Idd4 to a 5.2-cM region of chromosome 11 in NOD mice: identification of two potential candidate subloci. Diabetes 2002; 51: 215-223.
15. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988; 240: 659-662.
16. Adorini L, Gregori S, Harrison LC. Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med 2002; 8: 31-38.
17. Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes 1986; 35: 855-860.
18. Dilts SM, Solvason N, Lafferty KJ. The role of CD4 and CD8 T cells in the development of autoimmune diabetes. J Autoimmun 1999; 13: 285-290.
19. Wong FS, Visintin I, Wen L, Flavell RA, Janeway CA Jr. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996; 183: 67-76.
20. + T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996; 26: 1762-1769.
21. Lieberman SM, DiLorenzo TP. A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens 2003; 62: 359-377.
22. Wang B, Gonzalez A, Hoglund P, Katz JD, Benoist C, Mathis D. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 1998; 47: 1207-1211.
23. Serreze DV, Gaedeke JW, Leiter EH. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci U S A 1993; 90: 9625-9629.
24. Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003; 18: 41-51.
25. Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001; 7: 1057-1062.
26. Tung KS, Agersborg SS, Alard P, Garza KM, Lou YH. Regulatory T-cell, endogenous antigen and neonatal environment in the prevention and induction of autoimmune disease. Immunol Rev 2001; 182: 135-148.
27. + regulatory T cells. Nat Immunol 2003; 4: 330-336.
28. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73.
29. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331-337.
30. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21.
31. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
32. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8: 277-284.
33. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007; 445: 771-775.
34. Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445: 931-935.
35. Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005; 54: 306-310.
36. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338-344.
37. (+) regulatory T cells in the control of autoimmunity: in vivo veritas. Curr Opin Immunol 2008; 20: 655-662.
38. Hsieh CS, Zheng Y, Liang Y, Fontenot JD, Rudensky AY. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat Immunol 2006; 7: 401-410.
39. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164: 183-190.
40. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-296.
41. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008; 28: 546-558.
42. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
43. Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007; 7: 443-453.
44. + regulatory T cells abrogates their function in vivo. J Immunol 2006; 177: 4376-4383.
45. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 2008; 124: 13-22.
46. + regulatory T cells. J Immunol 2004; 172: 5986-5993.
47. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 2007; 104: 6335-6340.
48. + regulatory T cells. Proc Natl Acad Sci U S A 2007; 104: 2821-2826.
49. Dardenne M, Lepault F, Bendelac A, Bach JF. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning. Eur J Immunol 1989; 19: 889-895.
50. + regulatory T cells in the NOD mouse model of autoimmune diabetes. Proc Natl Acad Sci U S A 2007; 104: 18181-18186.
51. + regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008; 57: 113-123.
52. + regulatory T cells. J Immunol 2003; 171: 3348-3352.
53. +CD256+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440.
54. + T reg cells impinge on autoimmune diabetes. J Exp Med 2005; 202: 1387-1397.
55. + T cells in autoimmune diabetes. Nat Immunol 2001; 2: 1117-1125.
56. + regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci U S A 2004; 101(Suppl. 2): 14580-14585.
57. + cells in BDC2.5NOD mice. Immunology 2007; 121: 565-576.
58. You S, Belghith M, Cobbold S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005; 54: 1415-1422.
59. + regulatory T cells. Immunology 2007; 121: 15-28.
60. + regulatory T-cells in type 1 diabetes. Diabetes 2007; 56: 604-612.
61. + regulatory T cells during autoimmune diabetes. J Exp Med 2005; 201: 1333-1346.
62. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003; 171: 4040-4047.
63. Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006; 212: 217-237.
64. + T cell levels in NOD mice. Proc Natl Acad Sci U S A 2002; 99: 12287-12292.
65. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-140.
66. +) T-cells from patients with type 1 diabetes. Diabetes 2005; 54: 92-99.
67. +CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005; 24: 55-62.
68. + regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J Immunol 2008; 181: 6283-6292.
69. Tang Q, Adams JY, Tooley AJ, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7: 83-92.
70. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol 2005; 5: 343-349.
71. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003; 4: 664-669.
72. + cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J Immunol 2004; 173: 2942-2951.
73. Shinomiya M, Nadano S, Shinomiya H, Onji M. In situ characterization of dendritic cells occurring in the islets of nonobese diabetic mice during the development of insulitis. Pancreas 2000; 20: 290-296.
74. Nikolic T, Geutskens SB, van Rooijen N, Drexhage HA, Leenen PJ. Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulitis of the nonobese diabetic mouse: a phagocyte depletion study. Lab Invest 2005; 85: 487-501.
75. Vuckovic S, Withers G, Harris M, et al. Decreased blood dendritic cell counts in type 1 diabetic children. Clin Immunol 2007; 123: 281-288.
76. Prasad SJ, Goodnow CC. Cell-intrinsic effects of non-MHC NOD genes on dendritic cell generation in vivo. Int Immunol 2002; 14: 677-684.
77. Jansen A, van Hagen M, Drexhage HA. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 1995; 345: 491-492.
78. + immunoregulatory cells. J Immunol 2001; 167: 1137-1140.
79. + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30: 1538-1543.
80. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8: 191-197.
81. + regulatory T cells. J Immunol 2003; 170: 3939-3943.
82. + regulatory T cells in human thymus. Nature 2005; 436: 1181-1185.
83. Besin G, Gaudreau S, Menard M, Guindi C, Dupuis G, Amrani A. TSLP and TSLP-conditioned dendritic cells induce Treg differentiation and protection of NOD mice against diabetes. Diabetes 2008; 57(8): 2107-2117.
84. + regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235-247.
85. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-779.
86. Yadav D, Fine C, Azuma M, Sarvetnick N. B7-1 mediated costimulation regulates pancreatic autoimmunity. Mol Immunol 2007; 44: 2616-2624.
87. Yadav D, Judkowski V, Flodstrom-Tullberg M, et al. B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets. J Immunol 2004; 173: 3631-3639.
88. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145-1155.
89. + T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004; 199: 1479-1489.
90. + T cells in type 1 diabetes. Proc Natl Acad Sci U S A 2004; 101: 9345-9350.
91. + T cells. Immunity 2003; 19: 877-889.
92. Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, Bluestone JA. Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. J Clin Invest 2004; 114: 979-987.
93. Kumanogoh A, Wang X, Lee I, et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001; 166: 353-360.
94. +) T reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol 2005; 35: 557-567.
95. Yao Z, Kanno Y, Kerenyi M, et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 2007; 109: 4368-4375.
96. + T regulatory cells. J Immunol 2007; 178: 4062-4071.
97. + regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 2003; 171: 3435-3441.
98. + memory T cells. J Immunol 2003; 171: 5853-5864.
99. +) T cells: evidence for two distinct regulatory mechanisms. Eur J Immunol 2001; 31: 1637-1645.
100. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151.
101. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003; 74: 961-965.
102. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665-674.
103. + regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6: 1152-1159.
104. + regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J Immunol 2004; 173: 4994-5001.
105. + T lymphocytes. J Immunol 2005; 174: 155-163.
106. Yamanouchi J, Rainbow D, Serra P, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007; 39: 329-337.
107. +) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201: 723-735.
108. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28: 687-697.
109. Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 2007; 56: 1174-1176.
110. Wicker LS, Moule CL, Fraser H, et al. Natural genetic variants influencing type 1 diabetes in humans and in the NOD mouse. Novartis Found Symp 2005; 267: 57-65, discussion 65-75.
111. Kabelitz D, Geissler EK, Soria B, Schroeder IS, Fandrich F, Chatenoud L. Toward cell-based therapy of type I diabetes. Trends Immunol 2008; 29: 68-74.
112. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610-621.
113. + regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007; 204: 191-201.
114. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199: 1467-1477.